RBCC Explores 'Target-Rich Environment' as Biotechnology Takes Over San Francisco


RBCC Explores 'Target-Rich Environment' as Biotechnology Takes Over San Francisco

NOKOMIS, Fla.--(BUSINESS WIRE)-- The executive leadership of Rainbow Coral Corp. (OTCBB: RBCC) has returned from a business scouting trip to San Francisco with a thick stack of new potential ventures to pursue.

The bay area became the biotechnology industry's focus beginning last Monday with Biotech Showcase 2013. OneMedForum SF 2013 and the J.P. Morgan 31st Annual Healthcare Conference all descended on San Francisco at once. RBCC CEO Patrick Brown said today that the company will begin sorting through the dozens of new contacts that were made this week, searching for the most promising new partnering opportunities available in the booming biotech space.

"San Francisco was undeniably a target-rich environment for a company like ours, that helps brilliant innovators develop and commercialize their best ideas," he said. "The triple bill on the bay gave us a prime opportunity to review the deal flow of new therapeutics and diagnostics currently being readied for the marketplace. We'll begin narrowing down our options to move forward with the most promising of these biotech developers this week."

As the Company searches for its next partner, RBCC's biotech subsidiary Rainbow Biosciences remains close to a joint venture deal with Amarantus Bioscience, makers of exciting new diagnostic tools and therapies for neurological diseases such as Parkinson's.

Amarantus recently announced highly promising results in new animal trials of its forthcoming Parkinson's therapeutic, known as MANF.

For more information on RBCC and its biotechnology targets, please visit www.rainbowbiosciences.com/investors.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NAS: AMGN) , Cell Therapeutics, Inc. (NAS: CTIC) and Abbott Laboratories (NYS: ABT) .

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at www.rainbowbiosciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO

KEYWORDS: United States North America Florida


The article RBCC Explores 'Target-Rich Environment' as Biotechnology Takes Over San Francisco originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.